Evidence map›Paper›PMID 37876438›Full record

ArticleHeliyon2023

A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer.

Safayat Mahmud Khan, Tonmoy Das, Sajib Chakraborty, Abdul Matin Anamur Rashid Choudhury, Howlader Fazlul Karim, Munshi Akid Mostofa, Hasib Uddin Ahmed, Md Akmal Hossain, Florence Le Calvez-Kelm, Md Ismail Hosen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Safayat Mahmud KhanClinical Biochemistry and Translational Medicine Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
Tonmoy DasSystems Cell-Signalling Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
Sajib ChakrabortySystems Cell-Signalling Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
Abdul Matin Anamur Rashid ChoudhuryDepartment. Uro-Oncology, National Institute of Cancer Research Hospital, Bangladesh.
Howlader Fazlul KarimDepartment. Uro-Oncology, National Institute of Cancer Research Hospital, Bangladesh.
Munshi Akid MostofaDepartment. Uro-Oncology, National Institute of Cancer Research Hospital, Bangladesh.
Hasib Uddin AhmedClinical Biochemistry and Translational Medicine Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
Md Akmal HossainClinical Biochemistry and Translational Medicine Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
Florence Le Calvez-KelmGenomic Epidemiology Branch, International Agency for Research on Cancer (IARC), 69372, Lyon, France.
Md Ismail HosenClinical Biochemistry and Translational Medicine Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
Hossain Uddin ShekharClinical Biochemistry and Translational Medicine Laboratory, Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh.
University of Dhaka · BDNational Institute of Cancer Research and Hospital · BDCentre international de recherche sur le cancer · FR

Funding

World Health Organization 001
6 · The paper itself

Abstract

p53 pathway is important in tumorigenesis. However, no study has been performed to specifically investigate the role of p53 pathway genes in bladder cancer (BLCA). In this study, transcriptomics data of muscle invasive bladder cancer patients (n = 411) from The Cancer Genome Atlas (TCGA) were investigated. Using the hallmark p53 pathway gene set, the Non-Negative Matrix factorization (NMF) analysis identified two subtypes (C1 and C2). Clinical, survival, and immunological analysis were done to validate distinct characteristics of the subtypes. Pathway enrichment analysis showed the subtype C1 with poor prognosis having enrichment in genes of the immunity related pathways, where C2 subtype with better prognosis being enriched in genes of the steroid synthesis and drug metabolism pathways. A signature gene set consisting of

Indexed as

BiomarkerBLCADLX1DSC1EnrichmentNMFNomogramp53Signature-setTCGA

Identifiers

PMID37876438
PMCPMC10590981
OpenAlexW4387643705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.